Clinical Trials Logo

Prematurity clinical trials

View clinical trials related to Prematurity.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05391633 Enrolling by invitation - Premature Birth Clinical Trials

Maternal Voice and Quantitative EEG (qEEG)

Start date: February 15, 2022
Phase: N/A
Study type: Interventional

A short-term randomized, blinded placebo-controlled trial, in premature infants in the neonatal intensive care unit (NICU) at 33-35 weeks post-conceptional age, of recorded maternal voice on quantitative EEG (spectral power density) as a marker of development.

NCT ID: NCT04762992 Enrolling by invitation - Pre-Eclampsia Clinical Trials

LMWH for Treatment of Early Fetal Growth Restriction (HepaGrowth)

HepaGrowth
Start date: July 6, 2023
Phase: Phase 3
Study type: Interventional

Early fetal growth restriction (FGR) is associated with considerable fetal and neonatal morbimortality (Miller et al. 2008, Nardozza et al. 2017). Placental thrombosis, infarcts and hypercoagulability are frequently seen in these pregnancies, suggesting a role for the activation of the coagulation cascade in the genesis of FGR. Patients will be randomized for low-molecular weight heparin or standard of care, and the outcomes of both arms (gestational age at delivery, gestational and fetal morbidity) will be compared.

NCT ID: NCT04400396 Enrolling by invitation - Prematurity Clinical Trials

Effect of Target Fortified Human Milk on the Growth Quality of Very Preterm Infants (TargetFort)

TargetFort
Start date: February 1, 2020
Phase:
Study type: Observational

It is reported that the standard method for fortification of human milk (HM) overestimates the energy and protein densities of HM (Macedo MHNP 2018), thus originating infant undernutrition (Macedo AJP 2018). The target fortification, based on analysis of HM composition, is considered the gold-standard method (Rochow 2015, McLeod 2016). This observational mixed cohort study aims to assess if very preterm infants fed HM with target fortification have greater growth during hospital stay and better body composition at term post-menstrual age (PMA), than those fed HM with standard fortification.